Novartis Adds Companion Dx to Lumiracoxib Resubmission in Europe

A Novartis official suggested that the resubmission of lumiracoxib could be the "first example" of a molecular diagnostic-based "drug rescue" in the industry.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

Related Stories